Immune checkpoint inhibitors such as programed death 1 protein (PD-1) and programmed death ligand 1 (PD-L1) tremendously influence the immune therapeutic outcome in many types of tumor including GBM (34–37). This evidence concerns the gene CD274 and glioblastoma.